Kidney adiposity in obesity and chronic kidney disease: mechanisms, measurement, and clinical implications
- 1School of Medicine, Tulane University, New Orleans, LA, United States
Abstract
Kidney outcomes vary substantially among people with similar body mass index (BMI), and conventional measures of obesity do not specify the adipose compartments that lie closest to the kidney or the biological state of those tissues. Human imaging, physiological studies, and paired-tissue analyses now permit a more anatomically explicit account of kidney adiposity. Perirenal adipose tissue (PRAT), renal sinus adipose tissue (RSAT), and intrarenal lipid are distinct constructs and should not be collapsed into a single ‘fatty kidney’ construct. This critical narrative review examines kidney adiposity at the obesity–CKD interface using a claim-conditioned translational evidence continuum spanning association, partial independence from systemic adiposity, prospective association, human mechanistic support, treatment-associated depot remodeling, depot–renal response linkage, causal mediation, and treatment-effect modification. Selected kidney-associated fat measures are associated with albuminuria, filtration, intrarenal haemodynamics, and CKD status, and some signals persist after adjustment for BMI or visceral adipose tissue. In paired tissue from healthy kidney donors, PRAT and RSAT show distinct metabolic and immune profiles. However, much of the human evidence derives from cohorts enriched for type 2 diabetes, which limits extrapolation to non-diabetic obesity-associated CKD. Acquisition, segmentation, normalisation, external validation, and clinically useful thresholds also remain unsettled. Intervention studies show that selected kidney-associated fat measures can change with lifestyle or sodium-glucose cotransporter-2 inhibition, whereas major kidney-outcome trials often did not measure kidney-adiposity compartments. These parallel observations do not establish that depot remodeling mediates renal protection. Compartment-resolved assessment of kidney adiposity should therefore be regarded as a research strategy rather than a clinical classification. Its future value depends on incremental prognostic or decision information beyond eGFR, albuminuria, and validated CKD risk models, and on direct testing of whether depot modification contributes causally to kidney response.
Related
- Diagnostic Performance of Clinical Examination for Detecting Knee Effusion: Impact of Obesity and Periarticular Adiposity
- Dietary fatty acid profiles in obesity-associated female infertility: mechanisms and reproductive implications
- Obesity and Oral Health: Clinical Associations, Mechanistic Evidence, and Implications for Dental Care—A Narrative Review
- Diet, Obesity and Cardiovascular Health: Molecular Mechanisms, Clinical Evidence and Future Perspectives
- Selective Serotonin Reuptake Inhibitor-Associated Bruxism: Neuropharmacologic Mechanisms and Clinical Implications
BibTeX
@article{zhang2026kidney,
title = {{Kidney adiposity in obesity and chronic kidney disease: mechanisms, measurement, and clinical implications}},
author = {Yunxi Zhang},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1967640},
url = {https://doi.org/10.3389/fmed.2026.1967640},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Kidney adiposity in obesity and chronic kidney disease: mechanisms, measurement, and clinical implications
AU - Yunxi Zhang
PY - 2026
DA - 2026/10/22
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1967640
UR - https://doi.org/10.3389/fmed.2026.1967640
AB - Kidney outcomes vary substantially among people with similar body mass index (BMI), and conventional measures of obesity do not specify the adipose compartments that lie closest to the kidney or the biological state of those tissues. Human imaging, physiological studies, and paired-tissue analyses now permit a more anatomically explicit account of kidney adiposity. Perirenal adipose tissue (PRAT), renal sinus adipose tissue (RSAT), and intrarenal lipid are distinct constructs and should not be collapsed into a single ‘fatty kidney’ construct. This critical narrative review examines kidney adiposity at the obesity–CKD interface using a claim-conditioned translational evidence continuum spanning association, partial independence from systemic adiposity, prospective association, human mechanistic support, treatment-associated depot remodeling, depot–renal response linkage, causal mediation, and treatment-effect modification. Selected kidney-associated fat measures are associated with albuminuria, filtration, intrarenal haemodynamics, and CKD status, and some signals persist after adjustment for BMI or visceral adipose tissue. In paired tissue from healthy kidney donors, PRAT and RSAT show distinct metabolic and immune profiles. However, much of the human evidence derives from cohorts enriched for type 2 diabetes, which limits extrapolation to non-diabetic obesity-associated CKD. Acquisition, segmentation, normalisation, external validation, and clinically useful thresholds also remain unsettled. Intervention studies show that selected kidney-associated fat measures can change with lifestyle or sodium-glucose cotransporter-2 inhibition, whereas major kidney-outcome trials often did not measure kidney-adiposity compartments. These parallel observations do not establish that depot remodeling mediates renal protection. Compartment-resolved assessment of kidney adiposity should therefore be regarded as a research strategy rather than a clinical classification. Its future value depends on incremental prognostic or decision information beyond eGFR, albuminuria, and validated CKD risk models, and on direct testing of whether depot modification contributes causally to kidney response.
SN - 2296-858X
ER -